Immune Function of Colorectal Cancer Lymph Nodes
Launched by SHANXI PROVINCE CANCER HOSPITAL · Mar 12, 2024
Trial Information
Current as of July 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how lymph nodes, which are important parts of our immune system, affect the development of colorectal cancer. Lymph nodes help our bodies fight off diseases, including cancer, but their specific role in colorectal cancer is not well understood. Researchers will look at data from many patients to learn more about how these lymph nodes work in people with colorectal cancer.
To participate in this trial, you should be between 18 and 75 years old and have been diagnosed with stage I-III colorectal cancer. You need to be scheduled for surgery to remove the cancer, and your medical records should include detailed imaging and genetic information. However, if you have had treatment before surgery, other cancers, or severe infections, you may not be eligible. This trial is not yet recruiting participants, but it aims to gather more information that could help improve treatment and understanding of colorectal cancer in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Stage I-III colorectal cancer patients undergoing radical surgery
- • Complete imaging, pathology and genetics multi-omics data available
- • 18-75 years old
- Exclusion Criteria:
- • Patients with preoperative neoadjuvant therapy
- • Patients with incomplete clinical information
- • Patients with other malignant tumors
- • Patients with acute infections or untreated chronic infections
About Shanxi Province Cancer Hospital
Shanxi Province Cancer Hospital is a leading medical institution dedicated to cancer research, treatment, and patient care in Shanxi, China. With a commitment to advancing oncology through innovative clinical trials, the hospital integrates cutting-edge technologies and multidisciplinary expertise to enhance therapeutic outcomes. As a sponsor of clinical trials, Shanxi Province Cancer Hospital prioritizes patient safety and ethical standards while striving to contribute to the global body of cancer research. Its collaborative approach fosters partnerships with academic institutions and pharmaceutical companies, aiming to translate scientific discoveries into effective cancer treatments for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported